Prokaryotic expression, purification, and polyclonal antibody production against a novel drug resistance gene of Leishmania donovani clinical isolate.
Drug Target Discovery and Development Division, Central Drug Research Institute, Lucknow, India.
Journal Article: Protein Expression and Purification (impact factor: 1.56). 02/2006; 45(1):15-21. DOI: 10.1016/j.pep.2005.10.002
Abstract
Source: PubMed
Comments on this publication
ResearchGate members can add comments. Sign up now and post your comment!
Similar publications
In vitro activity of nicotinamide/antileishmanial drug combinations.
Parasitology international. 60(1):19-24.
Circumventing cancer drug resistance in the era of personalized medicine.
Cancer discovery. 2(3):214-26.
Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
International journal of oncology. 39(3):529-42.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

